ResearchPoint Global’s CEO, John Farinacci, spoke with WuXi Press about Genomics and Technology and how they are impacting the world of clinical trials.
SAMPLE: Advances in genomics are improving elements of drug development, such as design of clinical trial protocols, enrollment of patients and measurement of a potential drug’s effectiveness, but drug development still takes too long, is too expensive and too few drugs ever get approved.
“When you look at the available technology, the breakthroughs with biomarkers and genomics, it seems logical that we should be able to reduce the time and cost of drug development,” says John Farinacci, General Manager, WuXi Clinical Development Services (USA), Inc., formerly ResearchPoint Global (RPG). “As much as I wish I could tell you that is the case, there is no documented evidence out there to support that at this stage.”
However, Farinacci expects genomics eventually will accelerate drug development, reduce overall cost and improve outcomes industry-wide. He notes the science already is producing more effective treatments for patients. But in the near term, he says, the tech sector is likely to have the greatest impact on clinical trials “from advances in artificial intelligence, block chain, cloud computing and big data analytics.”